DNA damage signalling and repair inhibitors: The long-sought-after achilles’ heel of cancer

Biomolecules

Volumn 5, Issue 4, 2015, Pages 3204-3259

  Velic, Denis ^a,b,c   Couturier, Anthony M ^a,b   Ferreira, Maria Tedim ^b,d   Rodrigue, Amélie ^a,b   Poirier, Guy G ^b,d   Fleury, Fabrice ^c   Masson, Jean Yves ^a,b,d  

^a University Laval   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITÉ DE NANTES   (France)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

ATM; ATR; CHK1; CHK2; DNA repair; Inhibitors; MRE11; PARP; RAD51

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; ALPHA AMINO N [5,6 DIHYDRO 2 (1 METHYL 1H PYRAZOL 4 YL) 6 OXO 1H PYRROLO[4,3,2 EF][2,3]BENZODIAZEPIN 8 YL]CYCLOHEXANEACETAMIDE; ATM PROTEIN INHIBITOR; ATR PROTEIN INHIBITOR; AZ 20; AZD 6738; CHECKPOINT KINASE 1; CHECKPOINT KINASE INHIBITOR; CP 466722; DACTOLISIB; DNA DAMAGE RESPONSE INHIBITOR; ETP 46464; KU 59403; KU 60019; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MK 8776; NU 6027; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN INHIBITOR; RUCAPARIB; SCHIZANDRIN B; TALAZOPARIB; TORIN 2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VE 821; VELIPARIB; VX 970; ANTINEOPLASTIC AGENT; DNA LIGASE; ENZYME INHIBITOR;

APOPTOSIS; ATAXIA TELANGIECTASIA; BLADDER CANCER; CANCER THERAPY; CELL PROLIFERATION; COLORECTAL CARCINOMA; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; DRUG POTENCY; HIGH THROUGHPUT SCREENING; HUMAN; LUNG TUMOR; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN PHOSPHORYLATION; RADIOSENSITIZATION; REVIEW; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA DAMAGE; DNA REPAIR ENZYMES; ENZYME INHIBITORS; HUMANS; NEOPLASMS;

EID: 84975518665     PISSN: None     EISSN: 2218273X     Source Type: Journal    
DOI: 10.3390/biom5043204     Document Type: Review

References (302)

1. Ciccia, A.; Elledge, S.J. The DNA damage response: Making it safe to play with knives. Mol. Cell 2010, 40, 179-204.
2. Jackson, S.P.; Bartek, J. The DNA-damage response in human biology and disease. Nature 2009, 461, 1071-1078.
3. Savitsky, K.; Sfez, S.; Tagle, D.A.; Ziv, Y.; Sartiel, A.; Collins, F.S.; Shiloh, Y.; Rotman, G. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum. Mol. Genet. 1995, 4, 2025-2032.
4. Shiloh, Y. Ataxia telangiectasia and the nijmegen breakage syndrome: Related disorders but genes apart. Annu. Rev. Genet. 1997, 31, 635-662.
5. Bentley, N.J.; Holtzman, D.A.; Flaggs, G.; Keegan, K.S.; DeMaggio, A.; Ford, J.C.; Hoekstra, M.; Carr, A.M. The schizosaccharomyces pombe Rad3 checkpoint gene. EMBO J. 1996, 15, 6641-6651.
6. Cortez, D.; Guntuku, S.; Qin, J.; Elledge, S.J. ATR and ATRIP: Partners in checkpoint signaling. Science 2001, 294, 1713-1716.
7. San Filippo, J.; Sung, P.; Klein, H. Mechanism of eukaryotic homologous recombination. Ann. Rev. Biochem. 2008, 77, 229-257.
8. de Klein, A.; Muijtjens, M.; van Os, R.; Verhoeven, Y.; Smit, B.; Carr, A.M.; Lehmann, A.R.; Hoeijmakers, J.H. Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice. Curr. Biol. 2000, 10, 479-482.
9. Brown, E.J.; Baltimore, D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev. 2000, 14, 397-402.
10. O'Driscoll, M.; Ruiz-Perez, V.L.; Woods, C.G.; Jeggo, P.A.; Goodship, J.A. A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in seckel syndrome. Nat. Genet. 2003, 33, 497-501.
11. Marechal, A.; Zou, L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb. Symp. Quant. Biol. 2013, doi:10.1101/cshperspect.a012716.
12. Cortez, D. Unwind and slow down: Checkpoint activation by helicase and polymerase uncoupling. Genes Dev. 2005, 19, 1007-1012.
13. Cimprich, K.A.; Cortez, D. Atr: An essential regulator of genome integrity. Nat. Rev. Mol. Cell. Biol. 2008, 9, 616-627.
14. Sarkaria, J.N.; Busby, E.C.; Tibbetts, R.S.; Roos, P.; Taya, Y.; Karnitz, L.M.; Abraham, R.T. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res. 1999, 59, 4375-4382.
15. Cliby, W.A.; Roberts, C.J.; Cimprich, K.A.; Stringer, C.M.; Lamb, J.R.; Schreiber, S.L.; Friend, S.H. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J. 1998, 17, 159-169.
16. Mukhopadhyay, U.K.; Senderowicz, A.M.; Ferbeyre, G. Rna silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells. Cancer Res. 2005, 65, 2872-2881.
17. Cliby, W.A.; Lewis, K.A.; Lilly, K.K.; Kaufmann, S.H. S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J. Biol. Chem. 2002, 277, 1599-1606.
18. Won, J.; Kim, M.; Kim, N.; Ahn, J.H.; Lee, W.G.; Kim, S.S.; Chang, K.Y.; Yi, Y.W.; Kim, T.K. Retraction: Small molecule-based reversible reprogramming of cellular lifespan. Nat. Chem. Biol. 2008, doi:10.1038/nchembio0708-431.
19. Abraham, R.T. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 2001, 15, 2177-2196.
20. Price, B.D.; Youmell, M.B. The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Cancer Res. 1996, 56, 246-250.
21. Sarkaria, J.N.; Tibbetts, R.S.; Busby, E.C.; Kennedy, A.P.; Hill, D.E.; Abraham, R.T. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res. 1998, 58, 4375-4382.
22. Blasina, A.; Price, B.D.; Turenne, G.A.; McGowan, C.H. Caffeine inhibits the checkpoint kinase atm. Curr. Biol. 1999, 9, 1135-1138.
23. Tsabar, M.; Eapen, V.V.; Mason, J.M.; Memisoglu, G.; Waterman, D.P.; Long, M.J.; Bishop, D.K.; Haber, J.E. Caffeine impairs resection during DNA break repair by reducing the levels of nucleases Sae2 and Dna2. Nucleic Acids Res. 2015, doi:10.1093/nar/gkv520.
24. Newton, R.; Broughton, L.J.; Lind, M.J.; Morrison, P.J.; Rogers, H.J.; Bradbrook, I.D. Plasma and salivary pharmacokinetics of caffeine in man. Eur. J. Clin. Pharmacol. 1981, 21, 45-52.
25. Karve, S.; Werner, M.E.; Sukumar, R.; Cummings, N.D.; Copp, J.A.; Wang, E.C.; Li, C.; Sethi, M.; Chen, R.C.; Pacold, M.E.; et al. Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery. Proc. Natl. Acad. Sci. USA 2012, 109, 8230-8235.
26. Vlahos, C.J.; Matter, W.F.; Hui, K.Y.; Brown, R.F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one (ly294002). J. Biol. Chem. 1994, 269, 5241-5248.
27. Hall-Jackson, C.A.; Cross, D.A.; Morrice, N.; Smythe, C. Atr is a caffeine-sensitive, DNA-activated protein kinase with a substrate specificity distinct from DNA-PK. Oncogene 1999, 18, 6707-6713.
28. Hammond, E.M.; Denko, N.C.; Dorie, M.J.; Abraham, R.T.; Giaccia, A.J. Hypoxia links ATR and p53 through replication arrest. Mol. Cell. Biol. 2002, 22, 1834-1843.
29. Goodarzi, A.A.; Lees-Miller, S.P. Biochemical characterization of the ataxia-telangiectasia mutated (atm) protein from human cells. DNA repair 2004, 3, 753-767.
30. Stiff, T.; O'Driscoll, M.; Rief, N.; Iwabuchi, K.; Lobrich, M.; Jeggo, P.A. Atm and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res. 2004, 64, 2390-2396.
31. Cleary, J.M.; Shapiro, G.I. Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer. Curr. Oncol. Rep. 2010, 12, 87-94.
32. Gharbi, S.I.; Zvelebil, M.J.; Shuttleworth, S.J.; Hancox, T.; Saghir, N.; Timms, J.F.; Waterfield, M.D. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem. J. 2007, 404, 15-21.
33. Liu, Q.; Wang, J.; Kang, S.A.; Thoreen, C.C.; Hur, W.; Ahmed, T.; Sabatini, D.M.; Gray, N.S. Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin- 2(1h)-one (torin2) as a potent, selective and orally available mtor inhibitor for treatment of cancer. J. Med. Chem. 2011, 54, 1473-1480.
34. Liu, Q.; Xu, C.; Kirubakaran, S.; Zhang, X.; Hur, W.; Liu, Y.; Kwiatkowski, N.P.; Wang, J.; Westover, K.D.; Gao, P.; et al. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM and ATR. Cancer Res. 2013, 73, 2574-2586.
35. Hickson, I.; Zhao, Y.; Richardson, C.J.; Green, S.J.; Martin, N.M.B.; Orr, A.I.; Reaper, P.M.; Jackson, S.P.; Curtin, N.J.; Smith, G.C.M. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 2004, 64, 9152-9159.
36. Weber, A.M.; Ryan, A.J. ATM and ATR as therapeutic targets in cancer. Pharmacol. Ther. 2015, 149, 124-138.
37. Golding, S.E.; Rosenberg, E.; Valerie, N.; Hussaini, I.; Frigerio, M.; Cockcroft, X.F.; Chong, W.Y.; Hummersone, M.; Rigoreau, L.; Menear, K.A.; et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol. Cancer Ther. 2009, 8, 2894-2902.
38. Crescenzi, E.; Palumbo, G.; de Boer, J.; Brady, H.J.M. Ataxia telangiectasia mutated and P21CIP1 modulate cell survival of drug-induced senescent tumor cells: Implications for chemotherapy. Clin. Cancer Res. 2008, 14, 1877-1887.
39. Eaton, J.S.; Lin, Z.P.; Sartorelli, A.C.; Bonawitz, N.D.; Shadel, G.S. Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis. J. Clin. Invest. 2007, 117, 2723-2734.
40. Zhang, T.; Shen, Y.; Chen, Y.; Hsieh, J.T.; Kong, Z. The atm inhibitor KU55933 sensitizes radioresistant bladder cancer cells with dab2ip gene defect. Int. J. Radiat. Biol. 2015, 91, 368-378.
41. Toulany, M.; Mihatsch, J.; Holler, M.; Chaachouay, H.; Rodemann, H.P. Cisplatin-mediated radiosensitization of non-small cell lung cancer cells is stimulated by ATM inhibition. Radiother. Oncol. 2014, 111, 228-236.
42. Vecchio, D.; Daga, A.; Carra, E.; Marubbi, D.; Raso, A.; Mascelli, S.; Nozza, P.; Garre, M.L.; Pitto, F.; Ravetti, J.L.; et al. Pharmacokinetics, pharmacodynamics and efficacy on pediatric tumors of the glioma radiosensitizer ku60019. Int. J. Cancer 2015, 136, 1445-1457.
43. Biddlestone-Thorpe, L.; Sajjad, M.; Rosenberg, E.; Beckta, J.M.; Valerie, N.C.K.; Tokarz, M.; Adams, B.R.; Wagner, A.F.; Khalil, A.; Gilfor, D.; et al. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clin. Cancer Res. 2013, 19, 3189-3200.
44. McCabe, N.; Hanna, C.; Walker, S.M.; Gonda, D.; Li, J.; Wikstrom, K.; Savage, K.I.; Butterworth, K.T.; Chen, C.; Harkin, D.P.; et al. Mechanistic rationale to target PTEN-deficient tumor cells with inhibitors of the DNA damage response kinase ATM. Cancer Res. 2015.
45. Zhu, Y.; Mao, C.; Wu, J.; Li, S.; Ma, R.; Cao, H.; Ji, M.; Jing, C.; Tang, J. Improved ataxia telangiectasia mutated kinase inhibitor KU60019 provides a promising treatment strategy for non-invasive breast cancer. Oncology Lett. 2014, 8, 2043-2048.
46. Batey, M.A.; Zhao, Y.; Kyle, S.; Richardson, C.; Slade, A.; Martin, N.M.; Lau, A.; Newell, D.R.; Curtin, N.J. Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer. Mol. Cancer Ther. 2013, 12, 959-967.
47. Rainey, M.D.; Charlton, M.E.; Stanton, R.V.; Kastan, M.B. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res. 2008, 68, 7466-7474.
48. Węsierska-Gądek, J.; Heinzl, S. Interactions between ataxia telangiectasia mutated kinase inhibition, poly(adp-ribose) polymerase-1 inhibition and brca1 status in breast cancer cells. J. Cancer Prev. 2014, 19, 125-136.
49. Nishida, H.; Tatewaki, N.; Nakajima, Y.; Magara, T.; Ko, K.M.; Hamamori, Y.; Konishi, T. Inhibition of ATR protein kinase activity by schisandrin b in DNA damage response. Nucleic Acids Res. 2009, 37, 5678-5689.
50. Tatewaki, N.; Nishida, H.; Yoshida, M.; Ando, H.; Kondo, S.; Sakamaki, T.; Konishi, T. Differential effect of schisandrin b stereoisomers on ATR-mediated DNA damage checkpoint signaling. J. Pharmacol. Sci. 2013, 122, 138-148.
51. Li, L.; Lu, Q.; Shen, Y.; Hu, X. Schisandrin b enhances doxorubicin-induced apoptosis of cancer cells but not normal cells. Biochem. Pharmacol. 2006, 71, 584-595.
52. Xu, Y.; Liu, Z.; Sun, J.; Pan, Q.; Sun, F.; Yan, Z.; Hu, X. Schisandrin B prevents doxorubicin-induced chronic cardiotoxicity and enhances its anticancer activity in vivo. PLoS ONE 2011, 6, e28335.
53. Hou, W.; Gao, W.; Wang, D.; Liu, Q.; Zheng, S.; Wang, Y. The protecting effect of deoxyschisandrin and schisandrin b on HaCat cells against UVB-induced damage. PLoS ONE 2015, 10, e0127177.
54. Peasland, A.; Wang, L.Z.; Rowling, E.; Kyle, S.; Chen, T.; Hopkins, A.; Cliby, W.A.; Sarkaria, J.; Beale, G.; Edmondson, R.J.; et al. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br. J. Cancer 2011, 105, 372-381.
55. Sultana, R.; Abdel-Fatah, T.; Perry, C.; Moseley, P.; Albarakti, N.; Mohan, V.; Seedhouse, C.; Chan, S.; Madhusudan, S. Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells. PLoS ONE 2013, 8, e57098.
56. Knight, Z.A.; Gonzalez, B.; Feldman, M.E.; Zunder, E.R.; Goldenberg, D.D.; Williams, O.; Loewith, R.; Stokoe, D.; Balla, A.; Toth, B.; et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 2006, 125, 733-747.
57. Jang, N.Y.; Kim, D.H.; Cho, B.J.; Choi, E.J.; Lee, J.S.; Wu, H.G.; Chie, E.K.; Kim, I.A. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer. BMC Cancer 2015, 15, 89.
58. Toledo, L.I.; Murga, M.; Zur, R.; Soria, R.; Rodriguez, A.; Martinez, S.; Oyarzabal, J.; Pastor, J.; Bischoff, J.R.; Fernandez-Capetillo, O. A cell-based screen identifies Atr inhibitors with synthetic lethal properties for cancer-associated mutations. Nat. Struct. Mol. Biol. 2011, 18, 721-727.
59. Maira, S.M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; Chene, P.; de Pover, A.; Schoemaker, K.; et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 2008, 7, 1851-1863.
60. Matsushima, M.; Kikuchi, E.; Matsumoto, K.; Hattori, S.; Takeda, T.; Kosaka, T.; Miyajima, A.; Oya, M. Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model. Int. J. Oncol. 2015, 47, 377-383
61. Echeverry, N.; Ziltener, G.; Barbone, D.; Weder, W.; Stahel, R.A.; Broaddus, V.C.; Felley-Bosco, E. Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors. Cell Death Dis. 2015, doi:10.1038/cddis.2015.124.
62. Schrauwen, S.; Depreeuw, J.; Coenegrachts, L.; Hermans, E.; Lambrechts, D.; Amant, F. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. Gynecol. Oncol. 2015, 138, 165-173.
63. Konstantinidou, G.; Bey, E.A.; Rabellino, A.; Schuster, K.; Maira, M.S.; Gazdar, A.F.; Amici, A.; Boothman, D.A.; Scaglioni, P.P. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res. 2009, 69, 7644-7652.
64. Charrier, J.D.; Durrant, S.J.; Golec, J.M.; Kay, D.P.; Knegtel, R.M.; MacCormick, S.; Mortimore, M.; O'Donnell, M.E.; Pinder, J.L.; Reaper, P.M.; et al. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. J. Med. Chem. 2011, 54, 2320-2330.
65. Reaper, P.M.; Griffiths, M.R.; Long, J.M.; Charrier, J.-D.; MacCormick, S.; Charlton, P.A.; Golec, J.M.C.; Pollard, J.R. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. 2011, 7, 428-430.
66. Pires, I.M.; Olcina, M.M.; Anbalagan, S.; Pollard, J.R.; Reaper, P.M.; Charlton, P.A.; McKenna, W.G.; Hammond, E.M. Targeting radiation-resistant hypoxic tumour cells through ATR inhibition. Br. J. Cancer 2012, 107, 291-299.
67. Prevo, R.; Fokas, E.; Reaper, P.M.; Charlton, P.A.; Pollard, J.R.; McKenna, W.G.; Muschel, R.J.; Brunner, T.B. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol. Ther. 2012, 13, 1072-1081.
68. Huntoon, C.J.; Flatten, K.S.; Wahner Hendrickson, A.E.; Huehls, A.M.; Sutor, S.L.; Kaufmann, S.H.; Karnitz, L.M. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res. 2013, 73, 3683-3691.
69. Fokas, E.; Prevo, R.; Pollard, J.R.; Reaper, P.M.; Charlton, P.A.; Cornelissen, B.; Vallis, K.A.; Hammond, E.M.; Olcina, M.M.; Gillies McKenna, W.; et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis. 2012, doi:10.1038/cddis.2012.181.
70. Hall, A.B.; Newsome, D.; Wang, Y.; Boucher, D.M.; Eustace, B.; Gu, Y.; Hare, B.; Johnson, M.A.; Li, H.; Milton, S.; et al. Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget 2014, 5, 5674-5685.
71. Nakahara, T.; Tanaka, K.; Ohno, S.I.; Egawa, N.; Yugawa, T.; Kiyono, T. Activation of NF-κB by human papillomavirus 16 E1 limits E1-dependent viral replication through degradation of E1. J. Vir. 2015, 89, 5040-5059.
72. Foote, K.M.; Blades, K.; Cronin, A.; Fillery, S.; Guichard, S.S.; Hassall, L.; Hickson, I.; Jacq, X.; Jewsbury, P.J.; McGuire, T.M.; et al. Discovery of 4-{4-[(3r)-3-methylmorpholin-4-yl]-6-[1- (methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1h-indole (az20): A potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. J. Med. Chem. 2013, 56, 2125-2138.
73. Clack, G.; Lau, A.; Pierce, A.; Smith, S.; Stephens, C. O6.3 ATR inhibitor AZD6738. Ann. Oncol. 2015, doi:10.1093/annonc/mdv084.3.
74. Rhind, N.; Russell, P. Chk1 and cds1: Linchpins of the DNA damage and replication checkpoint pathways. J. Cell Sci. 2000, 113, 3889-3896.
75. Xu, N.; Libertini, S.; Black, E.J.; Lao, Y.; Hegarat, N.; Walker, M.; Gillespie, D.A. Cdk-mediated phosphorylation of Chk1 is required for efficient activation and full checkpoint proficiency in response to DNA damage. Oncogene 2012, 31, 1086-1094.
76. Goto, H.; Kasahara, K.; Inagaki, M. Novel insights into Chk1 regulation by phosphorylation. Cell Struct. Funct. 2015, 40, 43-50.
77. Goto, H.; Izawa, I.; Li, P.; Inagaki, M. Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti-cancer therapy? Cancer Sci. 2012, 103, 1195-1200.
78. Merry, C.; Fu, K.; Wang, J.; Yeh, I.J.; Zhang, Y. Targeting the checkpoint kinase Chk1 in cancer therapy. Cell Cycle 2010, 9, 279-283.
79. Walker, M.; Black, E.J.; Oehler, V.; Gillespie, D.A.; Scott, M.T. Chk1 C-terminal regulatory phosphorylation mediates checkpoint activation by de-repression of Chk1 catalytic activity. Oncogene 2009, 28, 2314-2323.
80. Smits, V.A.; Reaper, P.M.; Jackson, S.P. Rapid pikk-dependent release of Chk1 from chromatin promotes the DNA-damage checkpoint response. Curr. Biol. 2006, 16, 150-159.
81. Bryant, C.; Rawlinson, R.; Massey, A.J. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. BMC Cancer 2014, doi:10.1186/1471-2407-14-570.
82. Sorensen, C.S.; Hansen, L.T.; Dziegielewski, J.; Syljuasen, R.G.; Lundin, C.; Bartek, J.; Helleday, T. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat. Cell Biol. 2005, 7, 195-201.
83. Morgan, M.A.; Parsels, L.A.; Zhao, L.; Parsels, J.D.; Davis, M.A.; Hassan, M.C.; Arumugarajah, S.; Hylander-Gans, L.; Morosini, D.; Simeone, D.M.; et al. Mechanism of radiosensitization by the chk1/2 inhibitor azd7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res. 2010, 70, 4972-4981.
84. Wei, Y.; Yu, L.; Bowen, J.; Gorovsky, M.A.; Allis, C.D. Phosphorylation of histone H3 is required for proper chromosome condensation and segregation. Cell 1999, 97, 99-109.
85. Chen, Z.; Xiao, Z.; Gu, W.Z.; Xue, J.; Bui, M.H.; Kovar, P.; Li, G.; Wang, G.; Tao, Z.F.; Tong, Y.; et al. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int. J. Cancer 2006, 119, 2784-2794.
86. Chen, Z.; Xiao, Z.; Chen, J.; Ng, S.C.; Sowin, T.; Sham, H.; Rosenberg, S.; Fesik, S.; Zhang, H. Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. Mol. Cancer Ther. 2003, 2, 543-548.
87. Benada, J.; Macurek, L. Targeting the checkpoint to kill cancer cells. Biomolecules 2015, 5, 1912-1937.
88. Sarmento, L.M.; Povoa, V.; Nascimento, R.; Real, G.; Antunes, I.; Martins, L.R.; Moita, C.; Alves, P.M.; Abecasis, M.; Moita, L.F.; et al. Chk1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress. Oncogene 2015, 34, 2978-2990.
89. Grabauskiene, S.; Bergeron, E.J.; Chen, G.; Thomas, D.G.; Giordano, T.J.; Beer, D.G.; Morgan, M.A.; Reddy, R.M. Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer. J. Surg. Res. 2014, 187, 6-13.
90. Zhang, Y.; Hunter, T. Roles of Chk1 in cell biology and cancer therapy. Int. J. Cancer 2014, 134, 1013-1023.
91. Curtin, N.J. DNA repair dysregulation from cancer driver to therapeutic target. Nat. Rev. Cancer 2012, 12, 801-817.
92. Daud, A.I.; Ashworth, M.T.; Strosberg, J.; Goldman, J.W.; Mendelson, D.; Springett, G.; Venook, A.P.; Loechner, S.; Rosen, L.S.; Shanahan, F.; et al. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as Monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J. Clin. Oncol. 2015, 33, 1060-1066.
93. Garrett, M.D.; Collins, I. Anticancer therapy with checkpoint inhibitors: What, where and when? Trends Pharmacol. Sci. 2011, 32, 308-316.
94. Prudhomme, M. Novel checkpoint 1 inhibitors. Recent Pat. Anticancer Drug Discov. 2006, 1, 55-68.
95. Wang, Q.; Fan, S.; Eastman, A.; Worland, P.J.; Sausville, E.A.; O'Connor, P.M. Ucn-01: A potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst. 1996, 88, 956-965.
96. Welch, S.; Hirte, H.W.; Carey, M.S.; Hotte, S.J.; Tsao, M.S.; Brown, S.; Pond, G.R.; Dancey, J.E.; Oza, A.M. Ucn-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A study of the princess margaret hospital phase II consortium. Gynecol. Oncol. 2007, 106, 305-310.
97. Li, T.; Christensen, S.D.; Frankel, P.H.; Margolin, K.A.; Agarwala, S.S.; Luu, T.; Mack, P.C.; Lara, P.N., Jr.; Gandara, D.R. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: A california cancer consortium trial. Invest. New Drugs 2012, 30, 741-748.
98. Guzi, T.J.; Paruch, K.; Dwyer, M.P.; Labroli, M.; Shanahan, F.; Davis, N.; Taricani, L.; Wiswell, D.; Seghezzi, W.; Penaflor, E.; et al. Targeting the replication checkpoint using sch 900776, a potent and functionally selective Chk1 inhibitor identified via high content screening. Mol. Cancer Ther. 2011, 10, 591-602.
99. Engelke, C.G.; Parsels, L.A.; Qian, Y.; Zhang, Q.; Karnak, D.; Robertson, J.R.; Tanska, D.M.; Wei, D.; Davis, M.A.; Parsels, J.D.; et al. Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776. Clin. Cancer Res. 2013, 19, 4412-4421.
100. Grabauskiene, S.; Bergeron, E.J.; Chen, G.; Chang, A.C.; Lin, J.; Thomas, D.G.; Giordano, T.J.; Beer, D.G.; Morgan, M.A.; Reddy, R.M. Chk1 levels correlate with sensitization to pemetrexed by Chk1 inhibitors in non-small cell lung cancer cells. Lung Cancer 2013, 82, 477-484.
101. Chernikova, S.B.; Game, J.C.; Brown, J.M. Inhibiting homologous recombination for cancer therapy. Cancer Biol. Ther. 2012, 13, 61-68.
102. Venkatesha, V.A.; Parsels, L.A.; Parsels, J.D.; Zhao, L.; Zabludoff, S.D.; Simeone, D.M.; Maybaum, J.; Lawrence, T.S.; Morgan, M.A. Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition. Neoplasia 2012, 14, 519-525.
103. Hermann, P.C.; Huber, S.L.; Herrler, T.; Aicher, A.; Ellwart, J.W.; Guba, M.; Bruns, C.J.; Heeschen, C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1, 313-323.
104. Landau, H.J.; McNeely, S.C.; Nair, J.S.; Comenzo, R.L.; Asai, T.; Friedman, H.; Jhanwar, S.C.; Nimer, S.D.; Schwartz, G.K. The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells. Mol. Cancer Ther. 2012, 11, 1781-1788.
105. Kim, M.K.; James, J.; Annunziata, C.M. Topotecan synergizes with chek1 (Chk1) inhibitor to induce apoptosis in ovarian cancer cells. BMC Cancer 2015, doi:10.1186/s12885-015-1231-z.
106. Network., C.G.A.R. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474, 609-615.
107. King, C.; Diaz, H.; Barnard, D.; Barda, D.; Clawson, D.; Blosser, W.; Cox, K.; Guo, S.; Marshall, M. Characterization and preclinical development of LY2603618: A selective and potent Chk1 inhibitor. Invest. New Drugs 2014, 32, 213-226.
108. Calvo, E.; Chen, V.J.; Marshall, M.; Ohnmacht, U.; Hynes, S.M.; Kumm, E.; Diaz, H.B.; Barnard, D.; Merzoug, F.F.; Huber, L.; et al. Preclinical analyses and phase I evaluation of lY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer. Invest. New Drugs 2014, 32, 955-968.
109. Carrassa, L.; Damia, G. Unleashing Chk1 in cancer therapy. Cell Cycle 2011, 10, 2121-2128.
110. Matsuoka, S.; Huang, M.; Elledge, S.J. Linkage of atm to cell cycle regulation by the Chk2 protein kinase. Science 1998, 282, 1893-1897.
111. Ahn, J.; Urist, M.; Prives, C. The Chk2 protein kinase. DNA repair 2004, 3, 1039-1047.
112. Kass, E.M.; Ahn, J.; Tanaka, T.; Freed-Pastor, W.A.; Keezer, S.; Prives, C. Stability of checkpoint kinase 2 is regulated via phosphorylation at serine 456. J. Biol. Chem. 2007, 282, 30311-30321.
113. Lovly, C.M.; Yan, L.; Ryan, C.E.; Takada, S.; Piwnica-Worms, H. Regulation of Chk2 ubiquitination and signaling through autophosphorylation of serine 379. Mol. Cell. Biol. 2008, 28, 5874-5885.
114. Wang, B.; Matsuoka, S.; Carpenter, P.B.; Elledge, S.J. 53BP1, a mediator of the DNA damage checkpoint. Science 2002, 298, 1435-1438.
115. Lou, Z.; Minter-Dykhouse, K.; Wu, X.; Chen, J. Mdc1 is coupled to activated Chk2 in mammalian DNA damage response pathways. Nature 2003, 421, 957-961.
116. Mochan, T.A.; Venere, M.; DiTullio, R.A.; Halazonetis, T.D. 53BP1 and NFBD1/MDC1-Nbs1 function in parallel interacting pathways activating ataxia-telangiectasia mutated (ATM) in response to DNA damage. Cancer Res. 2003, 63, 8586-8591.
117. Lou, Z.; Minter-Dykhouse, K.; Franco, S.; Gostissa, M.; Rivera, M.A.; Celeste, A.; Manis, J.P.; van Deursen, J.; Nussenzweig, A.; Paull, T.T.; et al. MDC1 maintains genomic stability by participating in the amplification of ATM-dependent DNA damage signals. Mol. Cell 2006, 21, 187-200.
118. Minter-Dykhouse, K.; Ward, I.; Huen, M.S.Y.; Chen, J.; Lou, Z. Distinct versus overlapping functions of MDC1 and 53BP1 in DNA damage response and tumorigenesis. J. Cell Biol. 2008, 181, 727-735.
119. Blasina, A.; de Weyer, I.V.; Laus, M.C.; Luyten, W.H.; Parker, A.E.; McGowan, C.H. A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase. Curr. Biol. 1999, 9, 1-10.
120. Bahassi, E.M.; Ovesen, J.L.; Riesenberg, A.L.; Bernstein, W.Z.; Hasty, P.E.; Stambrook, P.J. The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage. Oncogene 2008, 27, 3977-3985.
121. Zhang, J.; Willers, H.; Feng, Z.; Ghosh, J.C.; Kim, S.; Weaver, D.T.; Chung, J.H.; Powell, S.N.; Xia, F. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol. Cell Biol. 2004, 24, 708-718.
122. Lountos, G.T.; Jobson, A.G.; Tropea, J.E.; Self, C.R.; Zhang, G.; Pommier, Y.; Shoemaker, R.H.; Waugh, D.S. Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy. J. Struct. Biol. 2011, 176, 292-301.
123. Pommier, Y.; Weinstein, J.N.; Aladjem, M.I.; Kohn, K.W. Chk2 molecular interaction map and rationale for Chk2 inhibitors. Clin. Cancer Res. 2006, 12, 2657-2661.
124. Hirao, A.; Kong, Y.Y.; Matsuoka, S.; Wakeham, A.; Ruland, J.; Yoshida, H.; Liu, D.; Elledge, S.J.; Mak, T.W. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 2000, 287, 1824-1827.
125. Jobson, A.G.; Cardellina, J.H.; Scudiero, D.; Kondapaka, S.; Zhang, H.; Kim, H.; Shoemaker, R.; Pommier, Y. Identification of a bis-guanylhydrazone [4,4'-diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase. Mol. Pharmacol. 2007, 72, 876-884.
126. Lountos, G.T.; Tropea, J.E.; Zhang, D.; Jobson, A.G.; Pommier, Y.; Shoemaker, R.H.; Waugh, D.S. Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor. Protein Sci. 2009, 18, 92-100.
127. Jobson, A.G.; Lountos, G.T.; Lorenzi, P.L.; Llamas, J.; Connelly, J.; Cerna, D.; Tropea, J.E.; Onda, A.; Zoppoli, G.; Kondapaka, S.; et al. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1hindole- 2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J. Pharm. Exp. Ther. 2009, 331, 816-826.
128. Caldwell, J.J.; Welsh, E.J.; Matijssen, C.; Anderson, V.E.; Antoni, L.; Boxall, K.; Urban, F.; Hayes, A.; Raynaud, F.I.; Rigoreau, L.J.M.; et al. Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2. J. Med. Chem. 2011, 54, 580-590.
129. Anderson, V.E.; Walton, M.I.; Eve, P.D.; Boxall, K.J.; Antoni, L.; Caldwell, J.J.; Aherne, W.; Pearl, L.H.; Oliver, A.W.; Collins, I.; et al. CCT241533 is a potent and selective inhibitor of Chk2 that potentiates the cytotoxicity of PARP inhibitors. Cancer Res. 2011, 71, 463-472.
130. Arienti, K.L.; Brunmark, A.; Axe, F.U.; McClure, K.; Lee, A.; Blevitt, J.; Neff, D.K.; Huang, L.; Crawford, S.; Pandit, C.R.; et al. Checkpoint kinase inhibitors: Sar and radioprotective properties of a series of 2-arylbenzimidazoles. J. Med. Chem. 2005, 48, 1873-1885.
131. Matijssen, C.; Silva-Santisteban, M.C.; Westwood, I.M.; Siddique, S.; Choi, V.; Sheldrake, P.; van Montfort, R.L.M.; Blagg, J. Benzimidazole inhibitors of the protein kinase Chk2: Clarification of the binding mode by flexible side chain docking and protein-ligand crystallography. Bioorg. Med. Chem. 2012, 20, 6630-6639.
132. Curman, D.; Cinel, B.; Williams, D.E.; Rundle, N.; Block, W.D.; Goodarzi, A.A.; Hutchins, J.R.; Clarke, P.R.; Zhou, B.B.; Lees-Miller, S.P.; et al. Inhibition of the g2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine. J. Biol. Chem. 2001, 276, 17914-17919.
133. Oliver, A.W.; Paul, A.; Boxall, K.J.; Barrie, S.E.; Aherne, G.W.; Garrett, M.D.; Mittnacht, S.; Pearl, L.H. Trans-activation of the DNA-damage signalling protein kinase Chk2 by t-loop exchange. EMBO J. 2006, 25, 3179-3190.
134. Sharma, V.; Tepe, J.J. Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine. Bioorg. Med. Chem. Lett. 2004, 14, 4319-4321.
135. Nguyen, T.N.T.; Saleem, R.S.Z.; Luderer, M.J.; Hovde, S.; Henry, R.W.; Tepe, J.J. Radioprotection by hymenialdisine-derived checkpoint kinase 2 inhibitors. ACS Chem. Biol. 2012, 7, 172-184.
136. Saleem, R.S.Z.; Lansdell, T.A.; Tepe, J.J. Synthesis and evaluation of debromohymenialdisinederived Chk2 inhibitors. Bioorg. Med. Chem. 2012, 20, 1475-1481.
137. Larson, G.; Yan, S.; Chen, H.; Rong, F.; Hong, Z.; Wu, J.Z. Identification of novel, selective and potent Chk2 inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 172-175.
138. Carlessi, L.; Buscemi, G.; Larson, G.; Hong, Z.; Wu, J.Z.; Delia, D. Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol. Cancer Ther. 2007, 6, 935-944.
139. Yu, Q.; La Rose, J.; Zhang, H.; Takemura, H.; Kohn, K.W.; Pommier, Y. Ucn-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced g(2)-m checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res. 2002, 62, 5743-5748.
140. Zabludoff, S.D.; Deng, C.; Grondine, M.R.; Sheehy, A.M.; Ashwell, S.; Caleb, B.L.; Green, S.; Haye, H.R.; Horn, C.L.; Janetka, J.W.; et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol. Cancer Ther. 2008, 7, 2955-2966.
141. Matthews, D.J.; Yakes, F.M.; Chen, J.; Tadano, M.; Bornheim, L.; Clary, D.O.; Tai, A.; Wagner, J.M.; Miller, N.; Kim, Y.D.; et al. Pharmacological abrogation of s-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell cycle 2007, 6, 104-110.
142. Ame, J.C.; Spenlehauer, C.; de Murcia, G. The parp superfamily. BioEssays 2004, 26, 882-893.
143. Otto, H.; Reche, P.A.; Bazan, F.; Dittmar, K.; Haag, F.; Koch-Nolte, F. In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs). BMC Genomics 2005, doi:10.1186/1471-2164-6-139.
144. Tartier, L.; Spenlehauer, C.; Newman, H.C.; Folkard, M.; Prise, K.M.; Michael, B.D.; Menissier-de Murcia, J.; de Murcia, G. Local DNA damage by proton microbeam irradiation induces poly(adp-ribose) synthesis in mammalian cells. Mutagenesis 2003, 18, 411-416.
145. Malanga, M.; Althaus, F.R. The role of poly(adp-ribose) in the DNA damage signaling network. Biochem. Cell Biol. 2005, 83, 354-364.
146. Curtin, N.J.; Szabo, C. Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond. JMAM 2013, 34, 1217-1256.
147. Ekblad, T.; Camaioni, E.; Schuler, H.; Macchiarulo, A. Parp inhibitors: Polypharmacology versus selective inhibition. FEBS J. 2013, 280, 3563-3575.
148. Lupo, B.; Trusolino, L. Inhibition of poly(adp-ribosyl)ation in cancer: Old and new paradigms revisited. Biochim. Biophys. Acta 2014, 1846, 201-215.
149. Kummar, S.; Chen, A.; Parchment, R.E.; Kinders, R.J.; Ji, J.; Tomaszewski, J.E.; Doroshow, J.H. Advances in using parp inhibitors to treat cancer. BMC Medicine 2012, doi:10.1186/1741-7015-10-25.
150. Rouleau, M.; Patel, A.; Hendzel, M.J.; Kaufmann, S.H.; Poirier, G.G. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 2010, 10, 293-301.
151. Farmer, H.; McCabe, N.; Lord, C.J.; Tutt, A.N.J.; Johnson, D.A.; Richardson, T.B.; Santarosa, M.; Dillon, K.J.; Hickson, I.; Knights, C.; et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434, 917-921.
152. Bryant, H.E.; Schultz, N.; Thomas, H.D.; Parker, K.M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N.J.; Helleday, T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(adp-ribose) polymerase. Nature 2005, 434, 913-917.
153. Tutt, A.N.; Lord, C.J.; McCabe, N.; Farmer, H.; Turner, N.; Martin, N.M.; Jackson, S.P.; Smith, G.C.; Ashworth, A. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb. Symp. Quant. Biol. 2005, 70, 139-148.
154. Petermann, E.; Orta, M.L.; Issaeva, N.; Schultz, N.; Helleday, T. Hydroxyurea-stalled replication forks become progressively inactivated and require two different Rad51-mediated pathways for restart and repair. Mol. Cell 2010, 37, 492-502.
155. Schlacher, K.; Christ, N.; Siaud, N.; Egashira, A.; Wu, H.; Jasin, M. Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by Mre11. Cell 2011, 145, 529-542.
156. Fong, P.C.; Boss, D.S.; Yap, T.A.; Tutt, A.; Wu, P.; Mergui-Roelvink, M.; Mortimer, P.; Swaisland, H.; Lau, A.; O'Connor, M.J.; et al. Inhibition of poly(adp-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009, 361, 123-134.
157. Tutt, A.; Robson, M.; Garber, J.E.; Domchek, S.M.; Audeh, M.W.; Weitzel, J.N.; Friedlander, M.; Arun, B.; Loman, N.; Schmutzler, R.K.; et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 2010, 376, 235-244.
158. Audeh, M.W.; Carmichael, J.; Penson, R.T.; Friedlander, M.; Powell, B.; Bell-McGuinn, K.M.; Scott, C.; Weitzel, J.N.; Oaknin, A.; Loman, N.; et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet 2010, 376, 245-251.
159. Turner, N.; Tutt, A.; Ashworth, A. Hallmarks of "brcaness" in sporadic cancers. Nat. Struct. Mol. Biol. 2004, 4, 814-819.
160. McCabe, N.; Turner, N.C.; Lord, C.J.; Kluzek, K.; Bialkowska, A.; Swift, S.; Giavara, S.; O'Connor, M.J.; Tutt, A.N.; Zdzienicka, M.Z.; et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-Ribose) polymerase inhibition. Cancer Res. 2006, 66, 8109-8115.
161. Peng, G.; Lin, S.Y. Exploiting the homologous recombination DNA repair network for targeted cancer therapy. World J. Clin. Oncol. 2011, 2, 73-79.
162. Turner, N.C.; Ashworth, A. Biomarkers of PARP inhibitor sensitivity. Breast Cancer Res. Treat. 2011, 127, 283-286.
163. Yap, T.A.; Sandhu, S.K.; Carden, C.P.; de Bono, J.S. Poly(Adp-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J. Clin. 2011, 61, 31-49.
164. Ferraris, D.V. Evolution of poly(ADP-Ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J. Med. Chem. 2010, 53, 4561-4584.
165. Davar, D.; Beumer, J.H.; Hamieh, L.; Tawbi, H. Role of PARP inhibitors in cancer biology and therapy. Curr. Med. Chem. 2012, 19, 3907-3921.
166. Kopetz, S.; Mita, M.M.; Mok, I.; Sankhala, K.K.; Moseley, J.; Sherman, B.M.; Bradley, C.R.; Tolcher, A.W. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-Ribose polymerase (PARP) in subjects with advanced solid tumors. J. Clin. Oncol. 2008, 26, 3577.
167. Kaufman, B.; Shapira-Frommer, R.; Schmutzler, R.K.; Audeh, M.W.; Friedlander, M.; Balmana, J.; Mitchell, G.; Fried, G.; Stemmer, S.M.; Hubert, A.; et al. Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation: An open-label phase II study. J. Clin. Oncol. 2013, doi:10.1200/JCO.2014.56.2728.
168. Mendes-Pereira, A.M.; Martin, S.A.; Brough, R.; McCarthy, A.; Taylor, J.R.; Kim, J.S.; Waldman, T.; Lord, C.J.; Ashworth, A. Synthetic lethal targeting of pten mutant cells with PARP inhibitors. EMBO Mol. Med. 2009, 1, 315-322.
169. Forster, M.D.; Dedes, K.J.; Sandhu, S.; Frentzas, S.; Kristeleit, R.; Ashworth, A.; Poole, C.J.; Weigelt, B.; Kaye, S.B.; Molife, L.R. Treatment with olaparib in a patient with pten-deficient endometrioid endometrial cancer. Nat. Rev. Clin. Oncol. 2011, 8, 302-306.
170. Dedes, K.J.; Wetterskog, D.; Mendes-Pereira, A.M.; Natrajan, R.; Lambros, M.B.; Geyer, F.C.; Vatcheva, R.; Savage, K.; Mackay, A.; Lord, C.J.; et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci. Transl. Med. 2010, doi:10.1126/scitranslmed.3001538.
171. Hunt, C.R.; Gupta, A.; Horikoshi, N.; Pandita, T.K. Does pten loss impair DNA double-strand break repair by homologous recombination? Clin. Cancer Res. 2012, 18, 920-922.
172. Fraser, M.; Zhao, H.; Luoto, K.R.; Lundin, C.; Coackley, C.; Chan, N.; Joshua, A.M.; Bismar, T.A.; Evans, A.; Helleday, T.; et al. PTEN deletion in prostate cancer cells does not associate with loss of Rad51 function: Implications for radiotherapy and chemotherapy. Clin. Cancer Res. 2012, 18, 1015-1027.
173. Minami, D.; Takigawa, N.; Takeda, H.; Takata, M.; Ochi, N.; Ichihara, E.; Hisamoto, A.; Hotta, K.; Tanimoto, M.; Kiura, K. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol. Cancer Res. 2013, 11, 140-148.
174. Faraoni, I.; Compagnone, M.; Lavorgna, S.; Angelini, D.F.; Cencioni, M.T.; Piras, E.; Panetta, P.; Ottone, T.; Dolci, S.; Venditti, A.; et al. BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. Biochim. Biophys. Acta 2015, 1852, 462-472.
175. Ajimura, M.; Leem, S.H.; Ogawa, H. Identification of new genes required for meiotic recombination in saccharomyces cerevisiae. Genetics 1993, 133, 51-66.
176. Parry, J.M.; Davies, P.J.; Evans, W.E. The effects of "cell age" upon the lethal effects of physical and chemical mutagens in the yeast, saccharomyces cerevisiae. Mol. Gen. Genet. 1976, 146, 27-35.
177. Carney, J.P.; Maser, R.S.; Olivares, H.; Davis, E.M.; Le Beau, M.; Yates, J.R.; Hays, L.; Morgan, W.F.; Petrini, J.H. The hMre11/hRad50 protein complex and nijmegen breakage syndrome: Linkage of double-strand break repair to the cellular DNA damage response. Cell 1998, 93, 477-486.
178. Stewart, G.S.; Maser, R.S.; Stankovic, T.; Bressan, D.A.; Kaplan, M.I.; Jaspers, N.G.; Raams, A.; Byrd, P.J.; Petrini, J.H.; Taylor, A.M. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell 1999, 99, 577-587.
179. Waltes, R.; Kalb, R.; Gatei, M.; Kijas, A.W.; Stumm, M.; Sobeck, A.; Wieland, B.; Varon, R.; Lerenthal, Y.; Lavin, M.F.; et al. Human Rad50 deficiency in a nijmegen breakage syndrome-like disorder. Am. J. Hum. Genet. 2009, 84, 605-616.
180. Xiao, Y.; Weaver, D.T. Conditional gene targeted deletion by cre recombinase demonstrates the requirement for the double-strand break repair MRE11 protein in murine embryonic stem cells. Nucleic Acids Res. 1997, 25, 2985-2991.
181. Luo, G.; Yao, M.S.; Bender, C.F.; Mills, M.; Bladl, A.R.; Bradley, A.; Petrini, J.H. Disruption of mRad50 causes embryonic stem cell lethality, abnormal embryonic development, and sensitivity to ionizing radiation. Proc. Natl. Acad. Sci. USA 1999, 96, 7376-7381.
182. Zhu, J.; Petersen, S.; Tessarollo, L.; Nussenzweig, A. Targeted disruption of the nijmegen breakage syndrome gene NBS1 leads to early embryonic lethality in mice. Curr. Biol. 2001, 11, 105-109.
183. Williams, R.S.; Moncalian, G.; Williams, J.S.; Yamada, Y.; Limbo, O.; Shin, D.S.; Groocock, L.M.; Cahill, D.; Hitomi, C.; Guenther, G.; et al. Mre11 dimers coordinate DNA end bridging and nuclease processing in double-strand-break repair. Cell 2008, 135, 97-109.
184. Dery, U.; Coulombe, Y.; Rodrigue, A.; Stasiak, A.; Richard, S.; Masson, J.Y. A glycine-arginine domain in control of the human MRE11 DNA repair protein. Mol. Cell Biol. 2008, 28, 3058-3069.
185. De Jager, M.; Dronkert, M.L.; Modesti, M.; Beerens, C.E.; Kanaar, R.; van Gent, D.C. DNA-binding and strand-annealing activities of human Mre11: Implications for its roles in DNA double-strand break repair pathways. Nucleic Acids Res. 2001, 29, 1317-1325.
186. Paull, T.T.; Gellert, M. The 3' to 5' exonuclease activity of Mre 11 facilitates repair of DNA double-strand breaks. Mol. Cell 1998, 1, 969-979.
187. Paull, T.T.; Gellert, M. NBS1 potentiates ATP-driven DNA unwinding and endonuclease cleavage by the Mre11/Rad50 complex. Genes Dev. 1999, 13, 1276-1288.
188. De Jager, M.; van Noort, J.; van Gent, D.C.; Dekker, C.; Kanaar, R.; Wyman, C. Human Rad50/Mre11 is a flexible complex that can tether DNA ends. Mol. Cell 2001, 8, 1129-1135.
189. Williams, R.S.; Dodson, G.E.; Limbo, O.; Yamada, Y.; Williams, J.S.; Guenther, G.; Classen, S.; Glover, J.N.M.; Iwasaki, H.; Russell, P.; et al. Nbs1 flexibly tethers Ctp1 and Mre11-Rad50 to coordinate DNA double-strand break processing and repair. Cell 2009, 139, 87-99.
190. Chapman, J.R.; Jackson, S.P. Phospho-dependent interactions between NBS1 and MDC1 mediate chromatin retention of the Mrn complex at sites of DNA damage. EMBO Rep. 2008, 9, 795-801.
191. Wang, H.; Shi, L.Z.; Wong, C.C.; Han, X.; Hwang, P.Y.; Truong, L.N.; Zhu, Q.; Shao, Z.; Chen, D.J.; Berns, M.W.; et al. The interaction of CtIP and Nbs1 connects CDK and ATM to regulate HR-mediated double-strand break repair. PLoS Genet. 2013, 9, e1003277.
192. Kobayashi, J.; Tauchi, H.; Sakamoto, S.; Nakamura, A.; Morishima, K.; Matsuura, S.; Kobayashi, T.; Tamai, K.; Tanimoto, K.; Komatsu, K. NBS1 localizes to γ-H2AX foci through interaction with the FHA/BRCT domain. Curr. Biol. 2002, 12, 1846-1851.
193. Paull, T.T. Making the best of the loose ends: Mre11/Rad50 complexes and Sae2 promote DNA double-strand break resection. DNA repair 2010, 9, 1283-1291.
194. Lee, J.H.; Paull, T.T. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 2005, 308, 551-554.
195. Ferretti, L.P.; Lafranchi, L.; Sartori, A.A. Controlling DNA-end resection: A new task for CDKs. Front. Genet. 2013, doi:10.3389/fgene.2013.00099.
196. Shibata, A.; Moiani, D.; Arvai, A.S.; Perry, J.; Harding, S.M.; Genois, M.M.; Maity, R.; van Rossum-Fikkert, S.; Kertokalio, A.; Romoli, F.; et al. DNA double-strand break repair pathway choice is directed by distinct Mre11 nuclease activities. Mol. Cell 2014, 53, 7-18.
197. Dupre, A.; Boyer-Chatenet, L.; Sattler, R.M.; Modi, A.P.; Lee, J.-H.; Nicolette, M.L.; Kopelovich, L.; Jasin, M.; Baer, R.; Paull, T.T.; et al. A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat. Chem. Biol. 2008, 4, 119-125.
198. Rass, E.; Grabarz, A.; Plo, I.; Gautier, J.; Bertrand, P.; Lopez, B.S. Role of Mre11 in chromosomal nonhomologous end joining in mammalian cells. Nat. Struct. Mol. Biol. 2009, 16, 819-824.
199. Tsuzuki, T.; Fujii, Y.; Sakumi, K.; Tominaga, Y.; Nakao, K.; Sekiguchi, M.; Matsushiro, A.; Yoshimura, Y.; MoritaT. Targeted disruption of the Rad51 gene leads to lethality in embryonic mice. Proc. Natl. Acad. Sci. USA 1996, 93, 6236-6240.
200. Baumann, P.; Benson, F.E.; West, S.C. Human rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell 1996, 87, 757-766.
201. Buisson, R.; Dion-Cote, A.M.; Coulombe, Y.; Launay, H.; Cai, H.; Stasiak, A.Z.; Stasiak, A.; Xia, B.; Masson, J.Y. Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat. Struct. Mol. Biol. 2010, 17, 1247-1254.
202. Davies, A.A.; Masson, J.Y.; McIlwraith, M.J.; Stasiak, A.Z.; Stasiak, A.; Venkitaraman, A.R.; West, S.C. Role of BRCA2 in control of the Rad51 recombination and DNA repair protein. Mol. Cell 2001, 7, 273-282.
203. Takata, M.; Sasaki, M.S.; Tachiiri, S.; Fukushima, T.; Sonoda, E.; Schild, D.; Thompson, L.H.; Takeda, S. Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs. Mol. Cell Biol. 2001, 21, 2858-2866.
204. Pellegrini, L.; Yu, D.S.; Lo, T.; Anand, S.; Lee, M.; Blundell, T.L.; Venkitaraman, A.R. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 2002, 420, 287-293.
205. Aihara, H.; Ito, Y.; Kurumizaka, H.; Yokoyama, S.; Shibata, T. The N-terminal domain of the human Rad51 protein binds DNA: Structure and a DNA binding surface as revealed by NMR. J. Mol. Biol. 1999, 290, 495-504.
206. Haaf, T.; Golub, E.I.; Reddy, G.; Radding, C.M.; Ward, D.C. Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes. Proc. Natl. Acad. Sci. USA 1995, 92, 2298-2302.
207. Raderschall, E.; Stout, K.; Freier, S.; Suckow, V.; Schweiger, S.; Haaf, T. Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res. 2002, 62, 219-225.
208. Maacke, H.; Jost, K.; Opitz, S.; Miska, S.; Yuan, Y.; Hasselbach, L.; Luttges, J.; Kalthoff, H.; Sturzbecher, H.W. DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene 2000, 19, 2791-2795.
209. Maacke, H.; Opitz, S.; Jost, K.; Hamdorf, W.; Henning, W.; Kruger, S.; Feller, A.C.; Lopens, A.; Diedrich, K.; Schwinger, E.; et al. Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int. J. Cancer 2000, 88, 907-913.
210. Mitra, A.; Jameson, C.; Barbachano, Y.; Sanchez, L.; Kote-Jarai, Z.; Peock, S.; Sodha, N.; Bancroft, E.; Fletcher, A.; Cooper, C.; et al. Overexpression of Rad51 occurs in aggressive prostatic cancer. Histopathology 2009, 55, 696-704.
211. Takenaka, T.; Yoshino, I.; Kouso, H.; Ohba, T.; Yohena, T.; Osoegawa, A.; Shoji, F.; Maehara, Y. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int. J. Cancer 2007, 121, 895-900.
212. Henning, W.; Stürzbecher, H.W. Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. Toxicology 2003, 193, 91-109.
213. Vispe, S.; Cazaux, C.; Lesca, C.; Defais, M. Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res. 1998, 26, 2859-2864.
214. Ito, M.; Yamamoto, S.; Nimura, K.; Hiraoka, K.; Tamai, K.; Kaneda, Y. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J. Gene Med. 2005, 7, 1044-1052.
215. Kiyohara, E.; Tamai, K.; Katayama, I.; Kaneda, Y. The combination of chemotherapy with HVJ-E containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma. Gene Ther. 2012, 19, 734-741.
216. Macara, I.G.; Cantley, L.C. Mechanism of anion exchange across the red cell membrane by band 3: Interactions between stilbenedisulfonate and NAP-taurine binding sites. Biochemistry 1981, 20, 5695-5701.
217. Ishida, T.; Takizawa, Y.; Kainuma, T.; Inoue, J.; Mikawa, T.; Shibata, T.; Suzuki, H.; Tashiro, S.; Kurumizaka, H. Dids, a chemical compound that inhibits Rad51-mediated homologous pairing and strand exchange. Nucleic Acids Res. 2009, 37, 3367-3376.
218. Lamont, K.R.; Hasham, M.G.; Donghia, N.M.; Branca, J.; Chavaree, M.; Chase, B.; Breggia, A.; Hedlund, J.; Emery, I.; Cavallo, F.; et al. Attenuating homologous recombination stimulates an aid-induced antileukemic effect. J. Exp. Med. 2013, 210, 1021-1033.
219. Hasham, M.G.; Donghia, N.M.; Coffey, E.; Maynard, J.; Snow, K.J.; Ames, J.; Wilpan, R.Y.; He, Y.; King, B.L.; Mills, K.D. Widespread genomic breaks generated by activation-induced cytidine deaminase are prevented by homologous recombination. Nat. Immunol. 2010, 11, 820-826.
220. Takaku, M.; Kainuma, T.; Ishida-Takaku, T.; Ishigami, S.; Suzuki, H.; Tashiro, S.; van Soest, R.W.M.; Nakao, Y.; Kurumizaka, H. Halenaquinone, a chemical compound that specifically inhibits the secondary DNA binding of Rad51. Genes cells 2011, 16, 427-436.
221. Huang, F.; Motlekar, N.A.; Burgwin, C.M.; Napper, A.D.; Diamond, S.L.; Mazin, A.V. Identification of specific inhibitors of human Rad51 recombinase using high-throughput screening. ACS Chem. Biol. 2011, 6, 628-635.
222. Huang, F.; Mazina, O.M.; Zentner, I.J.; Cocklin, S.; Mazin, A.V. Inhibition of homologous recombination in human cells by targeting Rad51 recombinase. J. Med. Chem. 2012, 55, 3011-3020.
223. Huang, F.; Mazin, A.V. A small molecule inhibitor of human Rad51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts. PLoS ONE 2014, 9, e100993.
224. Alagpulinsa, D.A.; Ayyadevara, S.; Shmookler Reis, R.J. A small-molecule inhibitor of Rad51 reduces homologous recombination and sensitizes multiple myeloma cells to doxorubicin. Front. Oncol. 2014, doi:10.3389/fonc.2014.00289.
225. Budke, B.; Logan, H.L.; Kalin, J.H.; Zelivianskaia, A.S.; Cameron McGuire, W.; Miller, L.L.; Stark, J.M.; Kozikowski, A.P.; Bishop, D.K.; Connell, P.P. RI-1: A chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. Nucleic Acids Res. 2012, 40, 7347-7357.
226. Bee, L.; Fabris, S.; Cherubini, R.; Mognato, M.; Celotti, L. The efficiency of homologous recombination and non-homologous end joining systems in repairing double-strand breaks during cell cycle progression. PLoS ONE 2013, 8, e69061.
227. Budke, B.; Kalin, J.H.; Pawlowski, M.; Zelivianskaia, A.S.; Wu, M.; Kozikowski, A.P.; Connell, P.P. An optimized Rad51 inhibitor that disrupts homologous recombination without requiring michael acceptor reactivity. J. Med. Chem. 2013, 56, 254-263.
228. Jensen, R.B.; Carreira, A.; Kowalczykowski, S.C. Purified human BRCA2 stimulates Rad51-mediated recombination. Nature 2010, 467, 678-683.
229. Zhu, J.; Zhou, L.; Wu, G.; Konig, H.; Lin, X.; Li, G.; Qiu, X.L.; Chen, C.F.; Hu, C.M.; Goldblatt, E.; et al. A novel small molecule Rad51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia. EMBO Mol. Med. 2013, 5, 353-365.
230. Zhu, J.; Chen, H.; Guo, X.E.; Qiu, X.L.; Hu, C.M.; Chamberlin, A.R.; Lee, W.H. Synthesis, molecular modeling, and biological evaluation of novel Rad51 inhibitors. Eur. J. Med. Chem. 2015, 96, 196-208.
231. Game, J.C.; Mortimer, R.K. A genetic study of X-ray sensitive mutants in yeast. Mutat. Res. 1974, 24, 281-292.
232. Rijkers, T.; van Den Ouweland, J.; Morolli, B.; Rolink, A.G.; Baarends, W.M.; Van Sloun, P.P.; Lohman, P.H.; Pastink, A. Targeted inactivation of mouse Rad52 reduces homologous recombination but not resistance to ionizing radiation. Mol. Cell. Biol. 1998, 18, 6423-6429.
233. Van Dyck, E.; Stasiak, A.Z.; Stasiak, A.; West, S.C. Binding of double-strand breaks in DNA by human Rad52 protein. Nature 1999, 398, 728-731.
234. Baumann, P.; West, S.C. Heteroduplex formation by human Rad51 protein: Effects of DNA end-structure, hRP-A and hRad52. J. Mol. Biol. 1999, 291, 363-374.
235. Singleton, M.R.; Wentzell, L.M.; Liu, Y.; West, S.C.; Wigley, D.B. Structure of the single-strand annealing domain of human Rad52 protein. Proc. Natl. Acad. Sci. USA 2002, 99, 13492-13497.
236. Kagawa, W.; Kurumizaka, H.; Ishitani, R.; Fukai, S.; Nureki, O.; Shibata, T.; Yokoyama, S. Crystal structure of the homologous-pairing domain from the human Rad52 recombinase in the undecameric form. Mol. Cell 2002, 10, 359-371.
237. Kagawa, W.; Kagawa, A.; Saito, K.; Ikawa, S.; Shibata, T.; Kurumizaka, H.; Yokoyama, S. Identification of a second DNA binding site in the human Rad52 protein. J. Biol. Chem. 2008, 283, 24264-24273.
238. Lieberman, R.; Xiong, D.; James, M.; Han, Y.; Amos, C.I.; Wang, L.; You, M. Functional characterization of RAD52 as a lung cancer susceptibility gene in the 12p13.33 locus. Mol. Carcinogen. 2015, doi:10.1002/mc.22334.
239. Lok, B.H.; Carley, A.C.; Tchang, B.; Powell, S.N. RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination. Oncogene 2013, 32, 3552-3558.
240. Feng, Z.; Scott, S.P.; Bussen, W.; Sharma, G.G.; Guo, G.; Pandita, T.K.; Powell, S.N. Rad52 inactivation is synthetically lethal with BRCA2 deficiency. Proc. Natl. Acad. Sci. USA 2011, 108, 686-691.
241. Grimme, J.M.; Spies, M. Fret-based assays to monitor DNA binding and annealing by Rad52 recombination mediator protein. Methods Mol. Biol. 2011, 745, 463-483.
242. Grimme, J.M.; Honda, M.; Wright, R.; Okuno, Y.; Rothenberg, E.; Mazin, A.V.; Ha, T.; Spies, M. Human Rad52 binds and wraps single-stranded DNA and mediates annealing via two hRad52-ssDNA complexes. Nucleic Acids Res. 2010, 38, 2917-2930.
243. Mao, Z.; Bozzella, M.; Seluanov, A.; Gorbunova, V. Comparison of nonhomologous end joining and homologous recombination in human cells. DNA Repair 2008, 7, 1765-1771.
244. Mao, Z.; Bozzella, M.; Seluanov, A.; Gorbunova, V. DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells. Cell cycle 2008, 7, 2902-2906.
245. Lieber, M.R.; Gu, J.; Lu, H.; Shimazaki, N.; Tsai, A.G. Nonhomologous DNA end joining (NHEJ) and chromosomal translocations in humans. Subcell. Biochem. 2010, 50, 279-296.
246. Davidson, D.; Amrein, L.; Panasci, L.; Aloyz, R. Small molecules, inhibitors of DNA-PK, targeting DNA repair, and beyond. Front. Pharmacol. 2013, doi:10.3389/fphar.2013.00005.
247. Wymann, M.P.; Bulgarelli-Leva, G.; Zvelebil, M.J.; Pirola, L.; Vanhaesebroeck, B.; Waterfield, M.D.; Panayotou, G. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of LYS-802, a residue involved in the phosphate transfer reaction. Mol. Cell. Biol. 1996, 16, 1722-1733.
248. Collis, S.J.; DeWeese, T.L.; Jeggo, P.A.; Parker, A.R. The life and death of DNA-PK. Oncogene 2004, 24, 949-961.
249. Chen, H.; Zeng, X.; Gao, C.; Ming, P.; Zhang, J.; Guo, C.; Zhou, L.; Lu, Y.; Wang, L.; Huang, L.; et al. A new arylbenzofuran derivative functions as an anti-tumour agent by inducing DNA damage and inhibiting PARP activity. Sci. Reports 2015, doi:10.1038/srep10893.
250. Wennstrom, S.; Downward, J. Role of phosphoinositide 3-kinase in activation of ras and mitogen-activated protein kinase by epidermal growth factor. Mol. Cell. Biol. 1999, 19, 4279-4288.
251. Veuger, S.J.; Curtin, N.J.; Richardson, C.J.; Smith, G.C.M.; Durkacz, B.W. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-Ribose) polymerase-1. Cancer Res. 2003, 63, 6008-6015.
252. Willmore, E.; de Caux, S.; Sunter, N.J.; Tilby, M.J.; Jackson, G.H.; Austin, C.A.; Durkacz, B.W. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase ii poisons used in the treatment of leukemia. Blood 2004, 103, 4659-4665.
253. Nutley, B.P.; Smith, N.F.; Hayes, A.; Kelland, L.R.; Brunton, L.; Golding, B.T.; Smith, G.C.M.; Martin, N.M.B.; Workman, P.; Raynaud, F.I. Preclinical pharmacokinetics and metabolism of a novel prototype DNA-pk inhibitor nu7026. Br. J. Cancer 2005, 93, 1011-1018.
254. Niazi, M.T.; Mok, G.; Heravi, M.; Lee, L.; Vuong, T.; Aloyz, R.; Panasci, L.; Muanza, T. Effects of DNA-dependent protein kinase inhibition by NU7026 on dna repair and cell survival in irradiated gastric cancer cell line n87. Curr. Oncol. 2014, 21, 91-96.
255. Tavecchio, M.; Munck, J.; Cano, C.; Newell, D.; Curtin, N. Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination. Cancer Chemother. Pharmacol. 2012, 69, 155-164.
256. Zhao, Y.; Thomas, H.D.; Batey, M.A.; Cowell, I.G.; Richardson, C.J.; Griffin, R.J.; Calvert, A.H.; Newell, D.R.; Smith, G.C.M.; Curtin, N.J. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res. 2006, 66, 5354-5362.
257. Tichy, A.; Durisova, K.; Salovska, B.; Pejchal, J.; Zarybnicka, L.; Vavrova, J.; Dye, N.; Sinkorova, Z. Radio-sensitization of human leukaemic molt-4 cells by DNA-dependent protein kinase inhibitor, NU7441. Radiat. Environ. Biophys. 2014, 53, 83-92.
258. Zhang, L.; Zhang, F.; Zhang, W.; Chen, L.; Gao, N.; Men, Y.; Xu, X.; Jiang, Y. Harmine suppresses homologous recombination repair and inhibits proliferation of hepatoma cells. Cancer Biol. Ther. 2015, doi:10.1080/15384047.2015.1078021.
259. Wu, L.; Zhang, J.; Wu, H.; Han, E. DNA-PKcs interference sensitizes colorectal cancer cells to a mTOR kinase inhibitor WAY-600. Biochem. Biophys. Res. Commun. 2015, 466, 547-553.
260. Munck, J.M.; Batey, M.A.; Zhao, Y.; Jenkins, H.; Richardson, C.J.; Cano, C.; Tavecchio, M.; Barbeau, J.; Bardos, J.; Cornell, L.; et al. Chemosensitisation of cancer cells by KU-0060648; a dual inhibitor of DNA-PK and PI-3K. Mol. Cancer Ther. 2012, 11, 1789-1798.
261. Robert, F.; Barbeau, M.; Ethier, S.; Dostie, J.; Pelletier, J. Pharmacological inhibition of DNA-PK stimulates Cas9-mediated genome editing. Genome Med. 2015, 7, 1-11.
262. Kashishian, A.; Douangpanya, H.; Clark, D.; Schlachter, S.T.; Eary, C.T.; Schiro, J.G.; Huang, H.; Burgess, L.E.; Kesicki, E.A.; Halbrook, J. DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer. Mol. Cancer Ther. 2003, 2, 1257-1264.
263. Allen, C.; Halbrook, J.; Nickoloff, J.A. Interactive competition between homologous recombination and non-homologous end Joining11NIH grant CA77693 to JAN. Mol. Cancer Res. 2003, 1, 913-920.
264. Bailey, S.M.; Brenneman, M.A.; Halbrook, J.; Nickoloff, J.A.; Ullrich, R.L.; Goodwin, E.H. The kinase activity of DNA-PK is required to protect mammalian telomeres. DNA Repair 2004, 3, 225-233.
265. Yasaei, H.; Gozaly-Chianea, Y.; Slijepcevic, P. Analysis of telomere length and function in radiosensitive mouse and human cells in response to DNA-PKcs inhibition. Genome Integr. 2013, doi:10.1186/2041-9414-4-2.
266. Shinohara, E.T.; Geng, L.; Tan, J.; Chen, H.; Shir, Y.; Edwards, E.; Halbrook, J.; Kesicki, E.A.; Kashishian, A.; Hallahan, D.E. DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs. Cancer Res. 2005, 65, 4987-4992.
267. Davidson, D.; Grenier, J.; Martinez-Marignac, V.; Amrein, L.; Shawi, M.; Tokars, M.; Aloyz, R.; Panasci, L. Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells. Invest. New Drugs 2012, 30, 1736-1742.
268. Davidson, D.; Coulombe, Y.; Martinez-Marignac, V.; Amrein, L.; Grenier, J.; Hodkinson, K.; Masson, J.Y.; Aloyz, R.; Panasci, L. Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells. Invest. New Drugs 2012, 30, 1248-1256.
269. Take, Y.; Kumano, M.; Hamano, Y.; Fukatsu, H.; Teraoka, H.; Nishimura, S.; Okuyama, A. OK-1035, a selective inhibitor of DNA-dependent protein kinase. Biochem. Biophys. Res. Commun. 1995, 215, 41-47.
270. Take, Y.; Kumano, M.; Teraoka, H.; Nishimura, S.; Okuyama, A. DNA-dependent protein kinase inhibitor (OK-1035) suppresses p21 expression in HCT116 cells containing wild-type p53 induced by adriamycin. Biochem. Biophys. Res. Commun. 1996, 221, 207-212.
271. Kruszewski, M.; Wojewódzka, M.; Iwaneńko, T.; Szumiel, I.; Okuyama, A. Differential inhibitory effect of OK-1035 on DNA repair in L5178Y murine lymphoma sublines with functional or defective repair of double strand breaks. Mut. Res. 1998, 409, 31-36.
272. Stockley, M.; Clegg, W.; Fontana, G.; Golding, B.T.; Martin, N.; Rigoreau, L.J.M.; Smith, G.C.M.; Griffin, R.J. Synthesis, crystal structure determination, and biological properties of the DNA-dependent protein kinase (DNA-PK) inhibitor 3-cyano-6-hydrazonomethyl-5-(4- pyridyl)pyrid-[1h]-2-one (OK-1035). Bioorg. Med. Chem. Lett. 2001, 11, 2837-2841.
273. Ismail, I.H.; Martensson, S.; Moshinsky, D.; Rice, A.; Tang, C.; Howlett, A.; McMahon, G.; Hammarsten, O. SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization. Oncogene 2003, 23, 873-882.
274. Ohta, T. Modification of genotoxicity by naturally occurring flavorings and their derivatives. Crit. Rev. Toxicol. 1993, 23, 127-146.
275. Durant, S.; Karran, P. Vanillins-A novel family of DNA-PK inhibitors. Nucl. Acids Res. 2003, 31, 5501-5512.
276. Wang, C.Y.; Lai, P.Y.; Chen, T.Y.; Chung, B.C. NR5A1 prevents centriole splitting by inhibiting centrosomal DNA-PK activation and β-catenin accumulation. Cell Commun. Signal 2014, doi10.1186/s12964-014-0055-9.
277. Guo, L.; Liu, X.; Nishikawa, K.; Plunkett, W. Inhibition of topoisomerase IIα and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials. Mol. Cancer Ther. 2007, 6, 1501-1508.
278. Onda, T.; Toyoda, E.; Miyazaki, O.; Seno, C.; Kagaya, S.; Okamoto, K.; Nishikawa, K. NK314, a novel topoisomerase ii inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase ii inhibitors. Cancer Lett. 2008, 259, 99-110.
279. Toyoda, E.; Kagaya, S.; Cowell, I.G.; Kurosawa, A.; Kamoshita, K.; Nishikawa, K.; Iiizumi, S.; Koyama, H.; Austin, C.A.; Adachi, N. NK314, a topoisomerase II inhibitor that specifically targets the α isoform. J. Biol. Chem. 2008, 283, 23711-23720.
280. Hisatomi, T.; Sueoka-Aragane, N.; Sato, A.; Tomimasu, R.; Ide, M.; Kurimasa, A.; Okamoto, K.; Kimura, S.; Sueoka, E. NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase IIα and DNA-dependent protein kinase. Blood 2011, 117, 3575-3584.
281. Mortensen, D.S.; Perrin-Ninkovic, S.M.; Shevlin, G.; Elsner, J.; Zhao, J.; Whitefield, B.; Tehrani, L.; Sapienza, J.; Riggs, J.R.; Parnes, J.S.; et al. Optimization of a series of triazole containing mammalian target of rapamycin (mTOR) kinase inhibitors and the discovery of CC-115. J. Med. Chem. 2015, 58, 5599-5608.
282. Shawi, M.; Chu, T.W.; Martinez-Marignac, V.; Yu, Y.; Gryaznov, S.M.; Johnston, J.B.; Lees-Miller, S.P.; Assouline, S.E.; Autexier, C.; Aloyz, R. Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes. PLoS ONE 2013, 8, e70428.
283. Qi, D.; Hu, Y.; Zhang, Y.; Peng, T.; Ji, W. Effect of KU70 expression on radiosensitivity in renal carcinoma 786-O cells. Cancer Cell Int. 2014, 14, 1-6.
284. Chen, X.; Zhong, S.; Zhu, X.; Dziegielewska, B.; Ellenberger, T.; Wilson, G.M.; MacKerell, A.D.; Tomkinson, A.E. Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair. Cancer Res. 2008, 68, 3169-3177.
285. Srivastava, M.; Nambiar, M.; Sharma, S.; Karki, S.S.; Goldsmith, G.; Hegde, M.; Kumar, S.; Pandey, M.; Singh, R.K.; Ray, P.; et al. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell 2012, 151, 1474-1487.
286. Sun, M.F.; Chen, H.Y.; Tsai, F.J.; Liu, S.H.; Chen, C.Y.; Chen, C.Y.C. Search for novel remedies to augment radiation resistance of inhabitants of fukushima and chernobyl disasters: Identifying DNA repair protein XRCC4 inhibitors. J. Biomol. Struct. Dyn. 2011, 29, 325-337.
287. Tobin, L.A.; Robert, C.; Rapoport, A.P.; Gojo, I.; Baer, M.R.; Tomkinson, A.E.; Rassool, F.V. Targeting abnormal DNA double strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias. Oncogene 2013, 32, 1784-1793.
288. Tobin, L.A.; Robert, C.; Nagaria, P.; Chumsri, S.; Twaddell, W.; Ioffe, O.B.; Greco, G.E.; Brodie, A.H.; Tomkinson, A.E.; Rassool, F.V. Targeting abnormal DNA repair in therapy-resistant breast cancers. Mol. Cancer Res. 2012, 10, 96-107.
289. Gelmon, K.A.; Tischkowitz, M.; Mackay, H.; Swenerton, K.; Robidoux, A.; Tonkin, K.; Hirte, H.; Huntsman, D.; Clemons, M.; Gilks, B.; et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011, 12, 852-861.
290. Lord, C.J.; McDonald, S.; Swift, S.; Turner, N.C.; Ashworth, A. A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA repair 2008, 7, 2010-2019.
291. Turner, N.C.; Lord, C.J.; Iorns, E.; Brough, R.; Swift, S.; Elliott, R.; Rayter, S.; Tutt, A.N.; Ashworth, A. A synthetic lethal sirna screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 2008, 27, 1368-1377.
292. Fang, Z.; Kozlov, S.; McKay, M.J.; Woods, R.; Birrell, G.; Sprung, C.N.; Murrell, D.F.; Wangoo, K.; Teng, L.; Kearsley, J.H.; et al. Low levels of ATM in breast cancer patients with clinical radiosensitivity. Genome Integr. 2010, doi:10.1186/2041-9414-1-9.
293. Tommiska, J.; Bartkova, J.; Heinonen, M.; Hautala, L.; Kilpivaara, O.; Eerola, H.; Aittomaki, K.; Hofstetter, B.; Lukas, J.; von Smitten, K.; et al. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene 2008, 27, 2501-2506.
294. Kang, B.; Guo, R.F.; Tan, X.H.; Zhao, M.; Tang, Z.B.; Lu, Y.Y. Expression status of ataxia-telangiectasia-mutated gene correlated with prognosis in advanced gastric cancer. Mutat. Res. 2008, 638, 17-25.
295. Ding, L.; Getz, G.; Wheeler, D.A.; Mardis, E.R.; McLellan, M.D.; Cibulskis, K.; Sougnez, C.; Greulich, H.; Muzny, D.M.; Morgan, M.B.; et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455, 1069-1075.
296. Boultwood, J. Ataxia telangiectasia gene mutations in leukaemia and lymphoma. J. Clin. Pathol. 2001, 54, 512-516.
297. Schaffner, C.; Stilgenbauer, S.; Rappold, G.A.; Dohner, H.; Lichter, P. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 1999, 94, 748-753.
298. Williamson, C.T.; Kubota, E.; Hamill, J.D.; Klimowicz, A.; Ye, R.; Muzik, H.; Dean, M.; Tu, L.; Gilley, D.; Magliocco, A.M.; et al. Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. EMBO Mol. Med. 2012, 4, 515-527.
299. Kubota, E.; Williamson, C.T.; Ye, R.; Elegbede, A.; Peterson, L.; Lees-Miller, S.P.; Bebb, D.G. Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines. Cell Cycle 2014, 13, 2129-2137.
300. Bang, Y.J.; Im, S.A.; Lee, K.W.; Cho, J.Y.; Song, E.K.; Lee, K.H.; Kim, Y.H.; Park, J.O.; Chun, H.G.; Zang, D.Y.; et al. Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer. J. Clin. Oncol. 2015, doi:10.1200/JCO.2014.60.0320.
301. Fojo, T.; Bates, S. Mechanisms of resistance to PARP inhibitors-Three and counting. Cancer Discov. 2013, 3, 20-23.
302. Mateos-Gomez, P.A.; Gong, F.; Nair, N.; Miller, K.M.; Lazzerini-Denchi, E.; Sfeir, A. Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination. Nature 2015, 518, 254-257.